Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
about
Progress in treatment of ANCA-associated vasculitisInterventions for renal vasculitis in adultsThe Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western CountriesRecent advances in understanding and treating vasculitisTherapeutic advances in the treatment of vasculitisRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesBiomarkers in vasculitisCurrent and future prospects in the management of granulomatosis with polyangiitis (Wegener's granulomatosis)Updates in ANCA-associated vasculitisGuidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.ANCA-associated vasculitis in childhood: recent advances.Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.Long-term follow-up of cyclophosphamide compared with azathioprine for initial maintenance therapy in ANCA-associated vasculitis.Is newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabAmerican Society of Nephrology quiz and questionnaire 2014: glomerular diseasesOverlap between dermatomyositis and ANCA vasculitides.Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab?Outcome and treatment of elderly patients with ANCA-associated vasculitis.Benefits of an expanded use of plasma exchange for anti-neutrophil cytoplasmic antibody-associated vasculitis within a dedicated clinical service.Update on diffuse alveolar hemorrhage and pulmonary vasculitis.Intravenous cyclophosphamide and plasmapheresis in dialysis-dependent ANCA-associated vasculitisLymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.Trends in Long-Term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Renal DiseaseLong-term outcome of patients with ANCA-associated vasculitis treated with plasma exchange: a retrospective, single-centre study.Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.ANCA Associated Mononeuritis Multiplex with Overlap in Vasculitic Syndromes.The pulmonary vasculitides.Diagnosis and management of pulmonary vasculitis.Advances in therapy for ANCA-associated vasculitis.Renal vasculitis in 2012: reclassification and the introduction of biologicals.Systemic polyarteritis nodosa in the young: a single-center experience over thirty-two years.Treatment of ANCA-associated vasculitis.Key advances in the clinical approach to ANCA-associated vasculitis.State of the art in the treatment of systemic vasculitides.The long-term outcomes of systemic vasculitis.Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis.Treatment of granulomatosis with polyangiitis (Wegener's).
P2860
Q21195258-BE4C6393-F044-48DC-8B23-9378507A13D0Q24187038-2CC5065B-F2B0-41E7-848A-AF077F2B6550Q26740451-6DFA3930-5E36-443B-BDCF-A7255A30FE83Q26747046-FC66767E-BAB4-41D6-83A4-DCCF1C155A73Q26750499-DE338E95-7EE6-4DD9-AD2D-C1AE242A082CQ26751357-133D71EB-2D03-42AB-AEDB-5BDE9B553439Q26776308-386BD26F-681B-4DB3-A5D4-A9561B3903A0Q26825345-1A5084C2-56EE-463A-822E-5E081BA82C9AQ27025692-FE72EE52-23CA-43D2-9768-09A481E5BD02Q28069897-E59BE820-94A5-43C9-8FDB-4FA406410689Q30276550-25F50D09-64E8-4A9B-ABD8-654A08520826Q33644574-F5C2437B-2E40-498A-845F-B1CE79D34BF3Q33771970-74DB43BC-C078-40AB-B3DE-E8EB3B38590DQ34124668-5CE3955D-E376-4D08-AF8A-7EDBB7452CADQ34124711-84FAF58D-80F3-4591-90AD-6A8E51012980Q35065425-5F2E2EAA-0E23-4169-AA35-66343382394FQ35278674-306AA1A2-54EB-40CE-8EF7-FCE3F5B7B366Q35310775-DBE671A9-EAAC-4D56-82E7-A6D14C3C7F41Q35662018-2113E523-E398-4E97-9A9E-1016A08BAB4EQ35777619-BF8B1BFD-3D1C-4001-84A9-CB71AED8BA49Q35816989-6E327F80-AA59-4D2B-80B3-A3BFE13F900DQ35836369-9422FBB0-F90E-44DC-B4A1-068CF8B87494Q36354929-3C10F37A-FC5D-4928-B4D2-68D8C2ADAEA8Q36583330-7A8EE023-1211-4A98-A594-0242FC33F76EQ36652819-3D485734-1BF6-41F1-9CCB-1CD9F88B62FBQ37037298-6158F04D-D26A-4F66-9D1A-05EEEF08590CQ37093451-E7525DF1-451E-43AD-8129-43C51CD423D1Q37106198-F42A4801-1C43-467A-A65A-E944B777CA6EQ37663661-55283545-F427-4781-B64F-365D88FA9C9EQ38017164-A2C0D5FF-1189-4FCF-BA6C-4264FBCD13E1Q38033433-67822952-2B07-459A-9509-448E5C6B48EFQ38034940-91C63857-E449-4AAA-8DFC-5E23F9E8F3A6Q38072294-A60139D4-60C2-4F34-9487-E7600B653138Q38113544-1EEE18E3-E3FE-4EA6-8C92-0222EB6A25C9Q38159916-C79C5191-AD20-450E-80B6-FDB8A1DD35A3Q38224803-82E6C967-058E-4CA2-BCF4-30706389CA51Q38263514-CF023315-597E-4A99-9CD6-C22450F6756AQ38324168-53EFB5E0-555E-4554-B706-738CDBE1A20FQ38334787-C80A4FC3-BC3B-4E02-BD21-A5798BC6E914Q38341601-D3EC46DD-0280-4240-86E8-863C95E5E2BD
P2860
Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@en
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@nl
type
label
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@en
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@nl
prefLabel
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@en
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@nl
P2093
P50
P1476
Pulse versus daily oral cyclop ...... sculitis: long-term follow-up.
@en
P2093
Caroline O Savage
Charles Pusey
Daniel Blockmans
David Jayne
EUVAS investigators
Kerstin Westman
Kirsten de Groot
Lorraine Harper
Luis Felipe Flores-Suarez
Matthew D Morgan
P304
P356
10.1136/ANNRHEUMDIS-2011-200477
P407
P577
2011-11-29T00:00:00Z